Tarlatamab |
カタログ番号GC72408
One-Click Copy Product Info
|
Tarlatamab（AMG-757）はδ様リガンド3（DLL 3）を標的とする二重特異性T細胞結合剤（BiTE）抗体である。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2307488-83-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Tarlatamab is a half-life extended bispecific T-cell engager molecule targeting delta-like ligand 3 (DLL3) [1]. Tarlatamab binds to DLL3 on the surface of tumour cells and CD3 on the surface of cytotoxic T lymphocytes (CTLs), resulting in T-cell activation, release of inflammatory cytokines, and CTL-mediated cell death of DLL3-expressing tumor cells [2]. Tarlatamab has been widely used to enhance T-cell infiltration and anti-tumor responses, as well as to induce the regression of xenograft tumors[3].
In vitro, Tarlatamab treatment (0.1nM) for 48 hours significantly inhibited the viability of SHP-77 cells and induced the production of cytokines and the release of cytotoxic granules[4].
In vivo, Tarlatamab treatment via intraperitoneal injection at a dose of 3mg/kg, once a week for 3 weeks, significantly inhibited tumor growth in the mice with small cell lung cancer (SCLC) and activated the activity of infiltrating T cells in the tumor tissues[4].
References:
[1] Mountzios G, Sun L, Cho B C, et al. Tarlatamab in small-cell lung cancer after platinum-based chemotherapy[J]. New England Journal of Medicine, 2025, 393(4): 349-361.
[2] Dhillon S. Tarlatamab: first approval[J]. Drugs, 2024, 84(8): 995-1003.
[3] You R, Estrada J, Zhan J, et al. 1189 Elucidating the effects of chemotherapy and immune checkpoint blockade on the activity of tarlatamab, a DLL3-targeting bispecific T cell engager molecule, in small cell lung cancer preclinical models[J]. 2023.
[4] Giffin M J, Cooke K, Lobenhofer E K, et al. AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer[J]. Clinical Cancer Research, 2021, 27(5): 1526-1537.
| Cell experiment [1]: | |
Cell lines | SHP-77 cells |
Preparation Method | SHP-77 cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum, 100U/ml penicillin, and 100μg/ml streptomycin at 37°C with 5% CO2 and 95% saturated atmospheric humidity. SHP-77 cells were co-cultivated with purified human CD3+ T cells at a cell ratio of 5:1 with a dose range of Tarlatamab (0, 0.001, 0.01, 0.1, 1, and 10nM) for 48 hours, cell viability was analyzed. |
Reaction Conditions | 0, 0.001, 0.01, 0.1, 1, and 10nM; 48h |
Applications | Tarlatamab treatment significantly reduced the cell viability of SHP-77 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Female NOD.Cg-PrkdcscidIl2rgtm1Sug/JicTac (NOG) mice |
Preparation Method | Female NOG mice were maintained under a 12h light and 12h dark cycle at a temperature of 25°C and humidity of 50%±10%, free with water and diet. After one week of adaptation, mice were implanted subcutaneously with patient-derived SCLC tumor fragments. When the average tumor volume was 94-123mm3, mice were administered 3mg/kg Tarlatamab by intraperitoneal injection on days 1, 8, and 15. Tumor volumes and body weights were measured twice a week until study end at day 23. |
Dosage form | 3mg/kg; once a week for 3 weeks; i.p. |
Applications | Tarlatamab treatment significantly inhibited the tumor volumes in mice with SCLC, without affecting body weights. |
References: | |
| Cas No. | 2307488-83-9 | SDF | |
| Formula | M.Wt | ||
| 溶解度 | Storage | Store at -20°C | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
-
Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)